Aurobindo Eyes Opportunities After Offloading Natrol For $550m
US-Based Nutritionals Firm To Be Sold After Six Years
Executive Summary
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
You may also be interested in...
Upbeat On Injectables, Aurobindo Is Hiking Capacities
Aurobindo expects revenues from injectables to increase to $650m-$700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets, though big-ticket M&A is ruled out.
Upbeat On Injectables, Aurobindo Hiking Capacities
Aurobindo expects revenues from injectables to increase to $650-700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets though big-ticket ones are ruled out.
Asia Deal Watch: CStone Partners With LegoChem On Novel ADC Candidate
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: